Quality of life, long-term survivors and long-term outcome from the ABC-02 study.

Authors
Bridgewater, J
Lopes, A
Palmer, D
Cunningham, D
Anthoney, A
Maraveyas, A
Madhusudan, S
Iveson, T
Valle, Juan W
Wasan, H
Affiliation
UCL Cancer Institute, UCL, London WC1E 6DD, UK
Issue Date
2016-04-26

Metadata
Show full item record
Abstract
The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL), describe the long-term survivors and provide a long-term outcome.
Citation
Quality of life, long-term survivors and long-term outcome from the ABC-02 study. 2016, 114 (9):965-71 Br J Cancer
Journal
British Journal of Cancer
URI
http://hdl.handle.net/10541/610748
DOI
10.1038/bjc.2016.64
PubMed ID
27115567
Type
Article
Language
en
ISSN
1532-1827
Collections